Latest News From "The Pink Sheet" DAILY

Silence-Intradigm Deal is Only Year-End Noise on Quiet RNAi Front

The only RNAi-focused merger of the year so far weds two minor players trying to build a much-needed drug delivery platform.   read more

 

Killing Part D Rebates For Duals Could Cost Pharma Another $12 Billion

As health care reform approaches a House-Senate conference, there is speculation that pharma will commit more money in order to keep the door closed on broader rebates.   read more

 

Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10

The Indian company has captured over half of the rituximab segment in the local market, earning close to $6 million in just over a year's time after launch of Rituxan generic Reditux.   read more

 

FDA Pushes Back Action Date For Nuvigil Label Expansion Due To New Data

Cephalon, which has positioned Nuvigil to replace Provigil as the latter sleep drugs faces patent expiry, hopes to add treatment of jet lag to label.   read more

 

Rx Price Hikes In Advance Of Health Bill Will Get OIG Probe

Sen. Bill Nelson continues campaign to extract more concessions from pharmaceutical industry as part of health care reform legislation.   read more

 

Patent Power: Roche Concedes Case Over Amgen's EPO

Roche will not launch its anemia drug Mircera in the U.S. until Amgen's latest patent expires in 2015 unless it obtains a license.   read more

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here